glp-1 by ro Launches Wegovy® Pill Through Integration with Novo Nordisk RO LAUNCHES ELI LILLY'S KWIKPEN®,

While berberine has shown some promise in managing type 2 diabetes and weight loss, its effectiveness is limited due to poor absorption in the intestines

A common factor in metabolic diseases like diabetes, inflammation is a key component of the body's natural immune defence mechanism to protect itself

In terms of therapeutic utility, insulin is problematic as chronic administration in non-diabetics has significant risk

doi:10.1001/jamapsychiatry.2025.4308 Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, Tow AC, Dermody SS, Prince MA, Jordan R, McKee SA, Fletcher PJ, Claus ED, Klein KR